北京昭衍新药研究中心股份有限公司（“昭衍新药”或“公司”）于2026年2月3日公布截至2026年1月31日的股份变动月报表。报告期内，公司H股（股票代码：06127）数量维持不变，A股（股票代码：603127）出现部分注销。
截至2026年1月底，H股股本数量118,995,206股，与上月持平；A股由630,482,128股减少至630,353,014股，减少部分为129,114股，为本月注销的库存A股。期内未见新增股份发行或其他类别股本变动。
公司公告显示，本月末公司已发行股份总数为749,348,220股。公司确认已遵守香港联合交易所有限公司《上市规则》及相关法律法规，本次注销事项获董事会正式授权批准。公告由联席公司秘书高大鹏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.